Oxaliplatin formulations

Abstract

The present invention provides a pharmaceutical liquid formulation of oxaliplatin for parenteral administration, said formulation comprising (i) oxaliplatin, (ii) water; and (iii) an additive selected from the group consisting of tartaric acid, a salt of tartaric acid, a pharmaceutically acceptable derivative of tartaric acid and mixtures thereof.

1 . A pharmaceutical liquid formulation of oxaliplatin for parenteral administration, said formulation comprising 
 (i) oxaliplatin,    (ii) water; and    (iii) an additive selected from the group consisting of tartaric acid, a salt of tartaric acid, a pharmaceutically acceptable derivative of tartaric acid and mixtures thereof.    
     
     
         2 . A formulation according to  claim 1  wherein the concentration of the additive is from about 0.01 mM to about 2.0 mM.  
     
     
         3 . A formulation according to  claim 1  wherein the concentration of the additive is from about 0.1 mM to about 1.0 mM.  
     
     
         4 . A formulation according to  claim 1  wherein the concentration of the additive is from about 0.1 mM to about 0.6 mM.  
     
     
         5 . A formulation according to  claim 1  wherein the concentration of the additive is from about 0.2 mM to about 0.6 mM.  
     
     
         6 . A formulation according to  claim 1  wherein the additive comprises sodium tartrate.  
     
     
         7 . A formulation according to  claim 1  wherein the concentration of oxaliplatin up to about 15 mg/ml.  
     
     
         8 . A formulation according to  claim 1  wherein the concentration of oxaliplatin up to about 7 mg/ml.  
     
     
         9 . A formulation according to  claim 1  wherein the pH of the formulation is in the range of from about 3 to about 7.  
     
     
         10 . A method for treating a cancer which comprises administering a pharmaceutical formulation according to  claim 1  to a patient in need thereof.  
     
     
         11 . A method for preparing a pharmaceutical formulation, the method comprising the steps of: 
 (i) dissolving oxaliplatin in water to form a solution;    (ii) dissolving in the solution an additive selected from the group consisting of a tartaric acid, a salt of tartaric acid, a pharmaceutically acceptable derivative of a pharmaceutically acceptable tartaric acid and mixtures thereof;    (iii) optionally, adjusting the pH of the solution with a pharmaceutically acceptable base.    
     
     
         12 . A method according to  claim 11  wherein the concentration of the additive is from about 0.01 mM to about 2.0 mM.  
     
     
         13 . A method according to  claim 11  wherein the concentration of the additive is from about 0.1 mM to about 1.0 mM.  
     
     
         14 . A method according to  claim 11  wherein the concentration of the additive is from about 0.1 mM to about 0.6 mM.  
     
     
         15 . A method according to  claim 11  wherein the concentration of the additive is from about 0.2 mM to about 0.6 mM.  
     
     
         16 . A method according to  claim 11  wherein the additive comprises a salt of a pharmaceutically acceptable acid and wherein the salt is a sodium salt.  
     
     
         17 . A method according to  claim 11  wherein the concentration of oxaliplatin is up to about 15 mg/ml.  
     
     
         18 . A method according to  claim 11  wherein the concentration of oxaliplatin is up to about 7 mg/ml.  
     
     
         19 . A method according to  claim 11  wherein the concentration of oxaliplatin is about 5 mg/ml.  
     
     
         20 . A method according to  claim 11  wherein the pharmaceutically acceptable base is sodium hydroxide.  
     
     
         21 . A method according to  claim 11  wherein the pH of the formulation is adjusted to be in the range of from 3 to 7.  
     
     
         22 . A pharmaceutical liquid formulation of oxaliplatin for parenteral administration, said formulation comprising 
 (i) about 5 mg/ml of oxaliplatin,    (ii) water, and    (iii) an additive consisting of tartaric acid and the sodium salt of tartaric acid,    wherein the concentration of the additive is about 0.2 mM and wherein the pH of the solution is from about 4.7 to about 5.5.    
     
     
         23 . A method for treating a cancer which comprises administering a pharmaceutical formulation according to  claim 22  to a patient in need thereof.  
     
     
         24 . A method for preparing a pharmaceutical formulation, the method comprising the steps of: 
 (i) dissolving oxaliplatin in water to form a solution;    (ii) dissolving tartaric acid in the solution;    (iii) adjusting the pH of the solution with sodium hydroxide such that it is in the range of from 4.7 to 5.5    wherein the concentration of oxaliplatin is about 5 mg/ml and the concentration of tartaric acid is about 0.2 mM.